• Explore /
  • Poster
  • / A phase I/II study of nivolumab, paclitaxel, and ramucirumab as second-line in advanced gastric cancer.

A phase I/II study of nivolumab, paclitaxel, and ramucirumab as second-line in advanced gastric cancer.

Abstract Poster

Authors

Shuichi Hironaka

Shuichi Hironaka

Clinical Trial Promotion Department, Chiba Cancer Center, Chiba, Japan

Shuichi Hironaka , Shigenori Kadowaki , Naoki Izawa , Tomohiro Nishina , Takeharu Yamanaka , Keiko Minashi , Kei Muro , Yu Sunakawa , Takeshi Kajiwara , Yuichiro Hayashi , Yutaka Kawakami , Takako Eguchi Nakajima

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Esophageal and Gastric Cancer and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

UMIN000025947

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr 352)

Abstract #

352

Poster Bd #

D7

Abstract Disclosures

Similar Posters

First Author: Tomohiro Nishina

First Author: Mashiro Okunaka

First Author: Ronan Joseph Kelly

First Author: Mariela A. Blum Murphy